Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection
JAMA Oncol
.
2020 Nov 1;6(11):1808-1809.
doi: 10.1001/jamaoncol.2020.3386.
Authors
David A Fabrizio
1
,
Priti Hegde
1
,
Brian Alexander
1
Affiliation
1
Foundation Medicine Inc, Cambridge, Massachusetts.
PMID:
32880611
DOI:
10.1001/jamaoncol.2020.3386
No abstract available
Publication types
Letter
Comment
MeSH terms
Biomarkers, Tumor
Humans
Immunotherapy*
Neoplasms* / genetics
Neoplasms* / pathology
Neoplasms* / therapy
Substances
Biomarkers, Tumor